博舒替尼对比伊马替尼治疗新诊断慢性期慢性髓性白血病:BFORE试验最终结果
多中心、开放标签、3期BFORE试验5年随访最终结果报告博舒替尼在新诊断慢性期慢性髓性白血病中的疗效与安全性。患者随机接受博舒替尼400 mg每日一次(n=268)或伊马替尼(n=268;3例未治疗)。5年累积主要分子学缓解率博舒替尼组高于伊马替尼组(73.9% vs 64.6%;比值比1.57[95%CI 1.08-2.28]),MR4和MR4.5率亦更高。最终结果支持博舒替尼400 mg每日一次作为新诊断慢性期慢性髓性白血病患者的标准治疗。
要点
- 5年累积MMR率博舒替尼组73.9% vs 伊马替尼组64.6%,比值比1.57(95%CI 1.08-2.28)。
- 博舒替尼组MR4率58.2% vs 伊马替尼组48.1%,MR4.5率47.4% vs 36.6%。
- 博舒替尼在Sokal各风险组中MR均优于伊马替尼,高危患者获益最大。
核心结论
- 最终结果支持博舒替尼400 mg每日一次作为新诊断慢性期慢性髓性白血病患者的标准治疗。
研究设计与样本
- 多中心、开放标签、3期BFORE试验,5年随访。
- 患者随机接受博舒替尼400 mg每日一次(n=268)或伊马替尼(n=268;3例未治疗)。
主要发现
- 研究完成时,博舒替尼组59.7%和伊马替尼组58.1%的患者仍在研究治疗中;两组中位治疗持续时间和研究时间均为55个月。
- 5年累积MMR率博舒替尼组73.9% vs 伊马替尼组64.6%(比值比1.57[95%CI 1.08-2.28])。
- 5年累积MR4率博舒替尼组58.2% vs 伊马替尼组48.1%(比值比1.50[95%CI 1.07-2.12]),MR4.5率博舒替尼组47.4% vs 伊马替尼组36.6%(比值比1.57[95%CI 1.11-2.22])。
- 博舒替尼在Sokal各风险组中MR均优于伊马替尼,高危患者获益最大。
- 治疗中出现的不良事件与12个月数据一致;5年随访后博舒替尼组和伊马替尼组心脏、积液、肾脏和血管治疗中出现的不良事件发生率增加,但总体未发现新的安全性信号。
临床怎么用
- 原文结论支持博舒替尼400 mg每日一次作为新诊断慢性期慢性髓性白血病患者的标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This analysis from the multicenter, open-label, phase 3 BFORE trial reports efficacy and safety of bosutinib in patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) after five years' follow-up. Patients were randomized to 400-mg once-daily bosutinib (n = 268) or imatinib (n = 268; three untreated). At study completion, 59.7% of bosutinib- and 58.1% of imatinib-treated patients remained on study treatment. Median duration of treatment and time on study was 55 months in both groups. Cumulative major molecular response (MMR) rate by 5 years was higher with bosutinib versus imatinib (73.9% vs. 64.6%; odds ratio, 1.57 [95% CI, 1.08-2.28]), as were cumulative MR4 (58.2% vs. 48.1%; 1.50 [1.07-2.12]) and MR4.5 (47.4% vs. 36.6%; 1.57 [1.11-2.22]) rates. Superior MR with bosutinib versus imatinib was consistent across Sokal risk groups, with greatest benefit seen in patients with high risk. Treatment-emergent adverse events (TEAEs) were consistent with 12-month data. After 5 years of follow-up there was an increase in the incidence of cardiac, effusion, renal, and vascular TEAEs in bosutinib- and imatinib-treated patients, but overall, no new safety signals were identified. These final results support 400-mg once-daily bosutinib as standard-of-care in patients with newly diagnosed CP CML.This trial was registered at www.clinicaltrials.gov as #NCT02130557.
引用
- Brümmendorf TH, Cortes JE, Milojkovic D, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022. PMID: 35643868. doi:10.1038/s41375-022-01589-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。